2024-512403-39-00撤回1 期
A study to test a new immunotherapy, ABX-001, alone and in combination with the marketed drug, pembrolizumab, for the treatment of tumors previously treated with other therapies.
Abalos Therapeutics GmbH5 个研究点 分布在 2 个国家目标入组 27 人开始时间: 2025年4月28日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 发起方
- 入组人数
- 27
- 试验地点
- 5
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Senior Director Clinical Operations
Scientific
Abalos Therapeutics GmbH
研究点 (5)
Loading locations...
相似试验
已完成
不适用
Phase I clinical trial of newly developed antigen peptide vaccine for advanced esophageal cancerAdvanced esophageal squamous cell carcinoma patietns treated with standart therapy includingn surgery, chemotherapy and radiotherapy, and all these treatments were failed.JPRN-UMIN000004662Chiba University5
已完成
不适用
The study to develop novel treatment for antibody-mediated rejection after organ transplantation.post-transplant antibody-mediated rejectionJPRN-UMIN000031863Tokyo Women's Medical University5
尚未招募
不适用
An exploratory clinical trial of immunotherapy before surgery in stomach cancer casestage I-III stomach cancerJPRN-UMIN000002919JIKEI UNIVERSITY SCHOOL OF MEDICINE50
已完成
3 期
A Clinical trial of Omicron-Based CovIran Barkat vaccine as a third injection dose in vaccinated population over 18 years of ageIRCT20171122037571N4SHIFAPHARMED Industrial Group Co210
已完成
1 期
Study to evaluate safety and possible adverse reactions, especially serious, with a vaccine for measles and rubella in healthy subjects.Measles and RubellaRBR-9hckj4Bio-Manguinhos/Fiocruz/MS